WO2013034116A1 - 对atp结合位点进行突变的血管内皮抑制素突变体 - Google Patents
对atp结合位点进行突变的血管内皮抑制素突变体 Download PDFInfo
- Publication number
- WO2013034116A1 WO2013034116A1 PCT/CN2012/081210 CN2012081210W WO2013034116A1 WO 2013034116 A1 WO2013034116 A1 WO 2013034116A1 CN 2012081210 W CN2012081210 W CN 2012081210W WO 2013034116 A1 WO2013034116 A1 WO 2013034116A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mutant
- seq
- endostatin
- amino acid
- activity
- Prior art date
Links
- 230000027455 binding Effects 0.000 title claims abstract description 56
- 230000002792 vascular Effects 0.000 title claims abstract description 5
- 230000003511 endothelial effect Effects 0.000 title abstract description 3
- 102000004472 Myostatin Human genes 0.000 title abstract 2
- 108010056852 Myostatin Proteins 0.000 title abstract 2
- 230000000694 effects Effects 0.000 claims abstract description 205
- 108091006112 ATPases Proteins 0.000 claims abstract description 129
- 102000057290 Adenosine Triphosphatases Human genes 0.000 claims abstract description 129
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 13
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 claims description 79
- 108010079505 Endostatins Proteins 0.000 claims description 79
- 238000000034 method Methods 0.000 claims description 57
- 150000001413 amino acids Chemical class 0.000 claims description 53
- 230000035772 mutation Effects 0.000 claims description 38
- 230000010595 endothelial cell migration Effects 0.000 claims description 35
- 229920001223 polyethylene glycol Polymers 0.000 claims description 31
- 230000002401 inhibitory effect Effects 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 29
- 239000002202 Polyethylene glycol Substances 0.000 claims description 27
- 230000004071 biological effect Effects 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 230000007423 decrease Effects 0.000 claims description 16
- 230000001965 increasing effect Effects 0.000 claims description 14
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 230000002829 reductive effect Effects 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 238000007792 addition Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 claims description 7
- 229940107698 malachite green Drugs 0.000 claims description 7
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 101500026378 Homo sapiens Endostatin Proteins 0.000 claims description 4
- 238000005415 bioluminescence Methods 0.000 claims description 4
- 230000029918 bioluminescence Effects 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- 102000002045 Endothelin Human genes 0.000 claims 1
- 108050009340 Endothelin Proteins 0.000 claims 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims 1
- 102000002852 Vasopressins Human genes 0.000 claims 1
- 108010004977 Vasopressins Proteins 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical group C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims 1
- 229960003726 vasopressin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 10
- 230000009036 growth inhibition Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 28
- 239000000047 product Substances 0.000 description 27
- 230000000875 corresponding effect Effects 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 102000004169 proteins and genes Human genes 0.000 description 26
- 241000588724 Escherichia coli Species 0.000 description 19
- 210000002889 endothelial cell Anatomy 0.000 description 19
- 238000003259 recombinant expression Methods 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 11
- 239000012130 whole-cell lysate Substances 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 229920001427 mPEG Polymers 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 210000003556 vascular endothelial cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 102000003505 Myosin Human genes 0.000 description 6
- 108060008487 Myosin Proteins 0.000 description 6
- 206010029113 Neovascularisation Diseases 0.000 description 6
- 102220580831 Serine/threonine-protein kinase STK11_K96R_mutation Human genes 0.000 description 6
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 6
- 102000008300 Mutant Proteins Human genes 0.000 description 5
- 108010021466 Mutant Proteins Proteins 0.000 description 5
- 238000003149 assay kit Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000012292 cell migration Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000001772 anti-angiogenic effect Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000002380 cytological effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 102220020162 rs397508045 Human genes 0.000 description 4
- 239000012898 sample dilution Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 102100021010 Nucleolin Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960005305 adenosine Drugs 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 108010044762 nucleolin Proteins 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 102200043604 rs111947397 Human genes 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 230000002407 ATP formation Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 description 2
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 238000003390 bioluminescence detection Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 102220103167 rs765304898 Human genes 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 102000022315 ATPase binding proteins Human genes 0.000 description 1
- 108091012179 ATPase binding proteins Proteins 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000004135 Bone phosphate Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- KJZZXPHBHFVFFV-MCDZGGTQSA-N C(CCCCC(=O)O)(=O)O.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 Chemical compound C(CCCCC(=O)O)(=O)O.[C@@H]1([C@H](O)[C@H](O)[C@@H](CO)O1)N1C=NC=2C(N)=NC=NC12 KJZZXPHBHFVFFV-MCDZGGTQSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000033816 Chronic lymphoproliferative disorder of natural killer cells Diseases 0.000 description 1
- 108010001463 Collagen Type XVIII Proteins 0.000 description 1
- 102000047200 Collagen Type XVIII Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 1
- 108091006109 GTPases Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101500026380 Mus musculus Endostatin Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229910020820 NaAc-HAc Inorganic materials 0.000 description 1
- 108010075285 Nucleoside-Triphosphatase Proteins 0.000 description 1
- 102000008021 Nucleoside-Triphosphatase Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102220532327 Testis-expressed protein 10_K76R_mutation Human genes 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002482 anti-endothelial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000006452 cellular component assembly Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003763 chloroplast Anatomy 0.000 description 1
- 208000014620 chronic lymphoproliferative disorder of NK-cells Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000004651 endocytosis pathway Effects 0.000 description 1
- 108700008165 endostar Proteins 0.000 description 1
- 230000004528 endothelial cell apoptotic process Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009465 prokaryotic expression Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 102220076678 rs146651027 Human genes 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to novel antitumor drugs. Specifically, the present invention provides a mutant of endostatin which has reduced ATPase activity and increased neovascularization inhibitory activity. The present invention also provides the use of the mutant in the treatment of a neovascular related disease such as a tumor. Background technique
- ES endogenous vascular inhibitor
- collagen XVIII having a carboxyl terminal molecular weight of 20 kDa, which has an activity of inhibiting endothelial cell migration, proliferation, and formation of a lumen.
- Recombinant endostatin can inhibit or even cure a variety of mouse tumors without drug resistance (Folkman J. et al. Cell 1997; 88:277-285; Folkman J. et al. Nature 1997; 390:404-407 ).
- Endo human endostatin expressed in E. coli (trade name: Endo) has become an anti-tumor drug, and its efficacy has been extensively proven in clinical trials with non-small cell lung cancer as the main indication.
- Endo is an ES variant with an additional amino acid sequence (MGGSHHHHH) at the N-terminus, which has better thermodynamic stability and biological activity than the native human ES expressed by yeast (Fu Y. et Al. Biochemistry 2010; 49:6420-6429).
- Multi-site PEG modification of oES is usually achieved by modifying the Lys side chain ⁇ -amino group, although prolonging the pharmacogen half-life but the biology of ES The activity was significantly reduced ( ⁇ , Shandong University PhD thesis, CNKL 2005).
- the ⁇ -end single point PEG Modification not only enhances the in vivo stability of ES, but also enhances the biological activity of ES (ZL200610011247.9), and its related products have entered the clinical trial stage.
- ES endothelial cell activity
- endothelial cell migration including inhibition of endothelial cell migration, proliferation and formation of lumens, and induction of endothelial cell apoptosis.
- Nucleolin on the cell membrane surface acts as a functional receptor for ES, which mediates ES endocytosis and downstream signaling pathways in endothelial cells (Shi HB, et al., Blood, 2007). , 110:2899-2906).
- nucleolin is also expressed on the surface of MDA-MB-435 membrane, a highly proliferating breast cancer cell, and can mediate the endocytosis of its ligand protein in MDA-MB-435 (Sven Christian, et al ., JCB, 2003, 163(4): 871-878).
- ES-binding proteins that can serve as potential ES receptors including integrins, tropomyosin, glypicans, laminin, and matrix metalloproteinase 2 (MMP-2) (Sudhakar, A., et al., 2003, Proc. Natl Acad. Sci.
- the classical ES biological activity assay is based on its inhibition of endothelial cell activity, including experiments that inhibit endothelial cell migration, proliferation, and lumen formation.
- the endothelial cells used mainly include human microvascular endothelial cells (HMEC) and human umbilical vein endothelial cells (HUVEC).
- HMEC human microvascular endothelial cells
- HAVEC human umbilical vein endothelial cells
- these methods are high in requirements for cell culture, complex in operation and subjective, accurate and reproducible. Poor (Li YH, et aL, 2011, Chin J Biologicals March, Vol. 24 No. 3: 320-323). Therefore, finding and improving the biological activity evaluation methods of ES and its variants is of great significance for ES drug development and quality monitoring.
- Adipic acid adenosine is the most basic energy substance in living organisms. Participating in various physiological and biochemical reactions in living organisms is of great significance for maintaining normal life activities. ATP can be produced by a variety of cellular metabolic pathways: The most typical eukaryotic organisms are synthesized by tribasic adenosine synthase in the main mitochondria under normal physiological conditions by oxidation, or by photosynthesis in the chloroplast of plants. . The main energy source for ATP synthesis is glucose and fatty acids. Under normal physiological conditions, the molar concentrations of ATP in cells and blood are 1-10 mM and 100 ⁇ , respectively.
- ATPase also known as triuretic adenosine
- ADP diuretic adenosine
- Pi pity chloride
- the energy produced by the reaction can be used to drive another chemical reaction that requires energy by transfer, a process that is widely used by all known life forms.
- high-energy bonds contained in GTP can also provide energy for protein biosynthesis.
- ATPases Although various ATPases differ in sequence and tertiary structure, they usually contain a P-loop structure as a binding motif for binding to ATP (Andrea T. Deyrup, et al, 1998, JBC, 273(16): 9450 -9456), and this P-loop structure has the following typical sequences: GXXGXXK (Driscoll, WJ, et al., 1995, Proc. Natl. Acad. Sci.
- cancer cells and proliferative phase including endothelial cells need to consume large amounts of ATP; on the other hand, cancer cells and proliferating cells use glucose to produce ATP with low efficiency. This is due to the fact that most cancer cells and proliferating cells produce ATP by the Warburg effect. Although the efficiency of ATP production in this way is very low, there are a large number of stacked units that can be used for cell structure assembly in the process. Blocks), but more conducive to cell proliferation (Matthew G., et al., 2009, Science, 324: 1029-1033). Summary of invention
- the present invention relates to a novel activity of protein ES, i.e., ATPase activity, i.e., ATPase activity. New uses and ES drug designs based on this new activity were also announced.
- ES has a strong ATPase activity.
- Myosin pig heart extraction
- the present invention discloses a novel method for detecting and evaluating ES biological activity, which can determine the conformation and organism of recombinantly prepared ES by biochemical means such as extracellular detection of ATPase activity of ES. Learning activity.
- biochemical means such as extracellular detection of ATPase activity of ES. Learning activity.
- the enzyme activity detection method is sensitive, accurate, quick and reproducible, and can be widely applied to the biological activity and quality evaluation of ES and its variants.
- the invention provides a method of detecting the biological activity of endostatin, or a variant thereof, a mutant or a PEG-modified product, the step comprising detecting the endostatin, or a variant thereof, a mutant or a PEG modification ATPase activity of the product.
- the ATPase activity of a product such as endostatin, or a variant thereof, a mutant or a PEG-modified product can be detected by a malachite green acid salt detection method or an ATP bioluminescence detection method, thereby determining the conformation of the recombinantly prepared ES product.
- biological activity for example, the ATPase activity of a product such as endostatin, or a variant thereof, a mutant or a PEG-modified product can be detected by a malachite green acid salt detection method or an ATP bioluminescence detection method, thereby determining the conformation of the recombinantly prepared ES product. And biological activity.
- ES can be endocytosed into vascular endothelial cells by nucleolin.
- nucleolin To test whether ES can exert ATPase activity in cells, one embodiment of the present invention detects ES ATPase activity in an in vivo environment such as endothelium cell lysate. The results indicate that ES can also exert ATPase activity in endothelial cell lysates.
- the present inventors have found that the amino acid sequence Gly-Ser-Glu-Gly-Pro-Leu-Lys at position 89-95 in the native ES sequence (SEQ ID NO. 1) has a conserved amino acid sequence GXXGXXK of the ATP-binding motif. (Driscoll, W. J" et al, 1995, Proc. Natl. Acad. Sci. USA, 92: 12328-12332). Among them, three amino acid residues (2 G and 1 K) in various genera It is highly conserved. The ATPase activity of ES can be altered by site-directed mutagenesis of the amino acid in the ATP-binding motif.
- the present invention compares in one embodiment for ES variant proteins having different N-terminal sequences. It was found that ES (N-4) with 4 amino acid residues deleted at the N-terminus has significantly higher ATPase activity than full-length ES, while N-4 has significantly lower cytological activity than ES and inhibits tumors in animals in previous reports. Activity (Fu Y. et al. Biochemistry 2010; 49: 6420-6429).
- mouse ES can completely cure mouse tumors (Folkman J. et al. Nature 1997; 390:404-407).
- mouse ES(MM) does not contain the classical ATP-binding motif in human ES (Fig. 1). Therefore, we first tested the ATPase activity of MM and found that the ATPase activity of MM was significantly lower than that of human ES. Only about one-fifth of the activity of human ES was observed, but the activity of inhibiting tumor was higher than that of human ES.
- ES mutants having the sequences set forth in SEQ ID NOS. 6-11, 13, 14, 15-27, and 30-31 all exhibit lower ATPase activity than ES and are equivalent or significant Higher than ES activity to inhibit endothelial cell migration.
- ES is an angiogenesis inhibitor protein whose basic function is to inhibit neovascularization by inhibiting endothelial cell activity, thereby treating diseases associated with neovascularization (such as tumor, macular degeneration, obesity). And diabetes, etc.), we believe that these ES mutants can have a stronger activity in inhibiting neovascularization-related diseases such as tumors.
- molecular cloning can be used to further design (eg, reduce) ATPase activity to design ES mutants, thereby achieving better inhibition of tumor and neovascular related diseases.
- ES drug eg, a compound having a high phospholipase activity.
- the present invention also provides a method of increasing the biological activity of endostatin, which comprises reducing ATPase activity of endostatin or a variant thereof. Specifically, it can be passed through genetic workers.
- the method comprises mutating the ATP-binding motif GXXGXXK of endostatin or a variant thereof, thereby obtaining an endostatin mutant having reduced ATPase activity, the endostatin mutant having enhanced biological activity, For example, an increased activity of inhibiting endothelial cell migration and an increased activity of inhibiting tumors.
- the present invention also provides an endostatin mutant having increased anti-angiogenic activity, wherein the mutant comprises a mutation at its ATP-binding site, and is associated with a corresponding wild-type endostatin or The mutant has a reduced ATPase activity compared to its variant.
- the mutant has a decrease in ATPase activity of at least about 30%, such as a decrease of at least about 50%, a decrease of at least about 70%, or a decrease of at least about 90, compared to the corresponding wild-type endostatin or a variant thereof. %.
- the ATPase activity of the mutant is retained only up to about 60-70%, such as up to about 50-60%, and up to about 40-50%, compared to the corresponding wild-type endostatin or a variant thereof. , retain up to approximately 30-40%, retain up to approximately 20-30%, retain up to approximately 10-20%, or retain less than 10% or less.
- the mutant does not have ATPase activity.
- the mutant comprises a mutation in its ATP binding motif as compared to the corresponding wild type endostatin or a variant thereof.
- the mutant comprises a mutation in a sequence corresponding to a Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues 89-95 of SEQ ID NO. 1, wherein The mutation is selected from the group consisting of a substitution, deletion or addition of one or several amino acid residues or a combination thereof, wherein the mutation results in a decrease or elimination of the ATPase activity of the mutant.
- the sequence of the mutant corresponding to the Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues 89-95 of SEQ ID NO. 1 is partially or
- the endostatin mutant of the invention comprises the following mutations: (a) the Gly amino acid residue corresponding to position 89 of SEQ ID NO. 1 is substituted with an amino acid selected from the group consisting of an uncharged amino acid or an aromatic Or deleted; or (b) the Gly amino acid residue corresponding to position 92 of SEQ ID NO. 1 is substituted or deleted from an uncharged amino acid; or (c) corresponds to the first of SEQ ID NO.
- the Lys amino acid residue at position 95 is substituted or deleted by an amino acid selected from a positively charged or uncharged amino acid; or (d) any combination of (a) to (c).
- the endostatin mutant of the present invention comprises the following mutations: (a) the Gly amino acid residue corresponding to position 89 of SEQ ID NO. 1 is substituted with an amino acid selected from the group consisting of Ala and Pro Or deleted; or (b) the Gly amino acid residue corresponding to position 92 of SEQ ID NO. 1 is substituted or deleted by Ala; or (c) the Lys amino acid residue corresponding to position 95 of SEQ ID NO. The group is substituted or deleted by an amino acid selected from Arg and Gin; or (d) any combination of (a)-(c).
- substituted amino acid can also be selected for the above substitution without affecting the charge distribution and conformation of the mutant protein molecule.
- the endostatin mutant of the invention comprises a sequence selected from the group consisting of SEQ ID NO. 6 - IK 13, 14, 15-27 and 30-31.
- the endostatin mutant of the present invention comprises a sequence selected from the group consisting of SEQ ID N0.6, SEQ ID ⁇ 10, 8 ( ⁇ 10 27 and 8 ( ⁇ 10 30).
- the above-described endostatin mutant of the present invention is a mutant of human endostatin.
- the present invention also provides a pharmaceutical composition comprising the endostatin mutant of the present invention as described above.
- the endostatin may be covalently linked to a PEG molecule.
- the molecular weight of the PEG molecule is, for example, 5-40 kD, such as 5-20 kD, or 20-40 kD, preferably the molecular weight of the PEG molecule is 20 kD, for example 20 kD monomethoxy polyethylene glycol For example, monomethoxy polyethylene glycol propionaldehyde (mPEG-ALD).
- the PEG molecule is covalently linked to the N-terminal alpha amino group of the endostatin.
- the present invention also provides a method of treating a tumor comprising administering to a tumor patient an endostatin mutant of the present invention as described above or a pharmaceutical composition of the present invention as described above.
- the present invention also relates to the use of an endostatin mutant as described above for the preparation of a medicament for treating a neovascular related disease.
- the neovascular related disease is a tumor.
- Figure 1 Sequence alignment of human and murine ES.
- Figure 2 Preparation of ES, ES mutants, ES variants and their mPEG modified products.
- FIG. 3 ES, ES variants and their mPEG modified products have ATPase activity.
- Figure 4 ES, ES variants and their mPEG-modified products in endothelial cell whole cell lysates It has ATPase activity.
- ATPase activity assay can be used to quickly and accurately determine the biological activity of ES, ES variants and their mPEG modified products.
- Figure 7 Comparison of the activity of ATP in whole cell lysates of endothelial cells degraded by ES mutants.
- Figure 8 Comparison of ES mutants inhibiting endothelial cell migration activity.
- Figure 9 Comparison of ATPase activity and inhibition of endothelial cell migration activity of Endu mutants.
- Figure 10 Natural human ES sequence.
- Figure 11 Human ES sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 12 Human N-4 sequence recombinantly expressed in E. coli, where the first amino acid at the N-terminus and the last amino acid K at the C-terminus are randomly deleted during recombinant expression.
- Figure 13 Endu sequence recombinantly expressed in E. coli, in which the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 14 ES001 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 15 ES003 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 16 ES004 sequence recombinantly expressed in E. coli, in which the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 17 ES005 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 18 ES006 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted upon recombinant expression. Can be randomly deleted during recombinant expression.
- Figure 35 Z009 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 36 Z101 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 37 Z103 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 38 Z104 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 39 ZN1 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 40 ZN2 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 41 ZN3 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 42 ZN4 sequence recombinantly expressed in E. coli, wherein the first amino acid M at the N-terminus can be randomly deleted during recombinant expression.
- Figure 43 Comparison of ES mutants, ES01 ES012, inhibiting endothelial cell migration activity.
- Figure 44 Comparison of ES mutants S01, S02, S09, S10 inhibiting endothelial cell migration activity.
- Figure 45 Comparison of ES mutant S12 inhibition of endothelial cell migration activity.
- Figure 46 Comparison of ES mutant Z005, Z006, Z008, Z009 inhibiting endothelial cell migration activity.
- Figure 47 Comparison of ES mutant Z101, Z103, Z104, ZN1, ZN2, ZN3, ZN4 inhibiting endothelial cell migration activity.
- Figure 48 Inhibitory effect of ES mutants on tumor growth in non-small cell lung cancer A549 at the animal level, (A) tumor volume, (B) tumor weight.
- ES refers to a natural endostatin, such as human endostatin having the sequence of SEQ ID NO. 1 (Fig. 10).
- An ES variant refers to a form of addition or deletion of 1-15 amino acids at the N-terminus or C-terminus based on the native ES sequence.
- the ES variant may be naturally produced, for example, when human ES is recombinantly expressed in E. coli, its first amino acid M can be randomly deleted, resulting in an ES variant having the sequence of SEQ ID NO. 2 (Fig. 11) .
- an ES variant (N-4) having a N-terminal deletion of 4 amino acids can be produced due to random cleavage at the N-terminus, having the sequence shown in SEQ ID NO. ⁇ lj (; Fig. 12), further, wherein the K at the C-terminus can also be randomly deleted.
- ES variants can also be artificially produced, for example, to promote protein expression and improve stability, Endu adds 9 additional amino acid residues of the sequence MGGSHHHHH at the N-terminus of the native ES, the variant has The sequence shown in SEQ ID NO. 4 (Fig. 13), wherein the first amino acid M can be randomly deleted upon recombinant expression.
- an ES variant refers to a naturally occurring one that has the same or similar activity of inhibiting neovascularization as the corresponding native ES, and has the same ATP-binding motif and the same or similar ATPase activity as the corresponding native ES. Or artificially produced ES variants.
- a mutant of ES refers to a mutant protein obtained by modifying an ATP-binding site of a native ES or ES variant, such as an amino acid site-directed mutation of an ATP-binding motif.
- ES, ES variants and ES mutant proteins used in the present invention were purchased from Xiansheng Maidjin Company except for Endu, and the rest were supplied by Beijing Proji Company.
- Polyethylene glycol (PEG) modified ES, Endu and N-4 were named mPEG-ES, mPEG-Endu and mPEG-N-4, respectively, which were a monomethoxy polyethylene glycol with a molecular weight of 20 kDa.
- Propionaldehyde (mPEG-ALD) is a product obtained by modifying an ES, Endu or N-4 molecule. The site of coupling is the activated mPEG-ALD aldehyde group and the N-terminal ⁇ -amino group of ES, Endu or N-4.
- ATPase activity This is a widely accepted and used method for detecting ATPase activity.
- the principle is that under acidic conditions, malachite green, molybdate and inorganic pity acid react to form a green substance, which can be detected in the wavelength range of 600-660 nm, and its absorbance and pitiate content are linear in a certain range. relationship.
- ATPase releases ADP and pity acid (Pi) during the hydrolysis of ATP, and the activity of ATPase is calculated by the amount of pity acid measured by the kit.
- This method is convenient and rapid, and is widely used in the analysis of Phosphatase activity, lipase activity, Nucleoside Triphosphatase activity and Phosphate content. Large flux drug screen Selected.
- the ATP binding motif usually has a P-loop structure.
- the P-loop structure has the following typical sequences: GXXGXXK, (G/A) XXXXGK (T/S), GXXXXGKS and GXXGXGKS.
- the ATP binding motif refers to the sequence of GXXGXXK. Among them, amino acid residues not substituted with X are more conservative in comparison. Typically, these ATP binding motifs can also bind to GTP.
- ATPase-binding protein molecule that binds to ATP, including the classical ATP-binding motif and the ATP-binding amino acid site other than the ATP-binding motif. These amino acids may be distant from the above ATP-binding motifs in the primary sequence of the protein, but amino acids involved in the interaction of ES with ATP/GTP in the tertiary structure, or substitutions or deletions of these amino acid positions may indirectly affect the conformation of the protein. ES interacts with ATP/GTP to alter the ATPase activity of ES.
- the present invention is based on the discovery of ES new activity (ATPase activity), and discloses a new method for evaluating the biological activity of ES, which is more convenient, accurate and reproducible than the existing method using endothelial cell migration measurement.
- ES new activity ATPase activity
- This provides an important research method for ES and its variants, mechanism studies of mutants, drug development and quality control.
- the invention provides a method of detecting the biological activity of endostatin, or a variant thereof, a mutant or a PEG-modified product, the step comprising detecting the endostatin, or a variant thereof, a mutant or a PEG modification ATPase activity of the product.
- the ATPase activity of a product such as endostatin, or a variant thereof, a mutant or a PEG-modified product can be detected by a malachite green acid salt detection method or an ATP bioluminescence detection method, thereby determining the conformation of the recombinantly prepared ES product.
- biological activity for example, the ATPase activity of a product such as endostatin, or a variant thereof, a mutant or a PEG-modified product can be detected by a malachite green acid salt detection method or an ATP bioluminescence detection method, thereby determining the conformation of the recombinantly prepared ES product. And biological activity.
- the N-terminal ⁇ -amino group of ES and Endu was significantly modified by mPEG single-point modification, and the activity of inhibiting endothelial cell migration was significantly enhanced (ZL200610011247.9). Therefore, in one embodiment of the present invention, the ATPase activities of mPEG-ES, mPEG-Endu and mPEG-N-4 were simultaneously detected and found to be significantly lower than before the modification (Fig. 3).
- the present invention also provides a method of increasing the biological activity of endostatin, which comprises reducing ATPase activity of endostatin or a variant thereof.
- the ATP-binding motif GXXGXXK of endostatin or a variant thereof can be mutated by genetic engineering means to obtain an endostatin mutant having reduced ATPase activity, and the endostatin mutant has Increased biological activity, such as increased activity of inhibiting endothelial cell migration and increased tumor suppressor activity.
- ES can be endocytosed by endothelial cells, thereby degrading ATP in cells, living cells can quickly compensate for the consumption of ATP.
- the prior art usually detects ATP content in living cells by detecting ATP degradation of whole cell lysates. .
- the ATPase activities of the mutants ES003, ES006, ES007 and ES008 were still significantly lower than ES (Fig. 7A).
- the ATPase activities of the mutants ES001, ES004 and ES005 were comparable to those of ES (Fig. 7B). This may be due to the interaction of the P-loop structure caused by the mutation affecting the interaction of the entire protein with ATP.
- the present invention also provides an endostatin mutant having enhanced anti-angiogenic activity, wherein the mutant comprises a mutation at its ATP-binding site, and is associated with a corresponding wild-type vascular endothelial inhibition ATPase activity of the mutant compared to its variant or its variant Lower.
- the mutant has a decrease in ATPase activity of at least about 30%, such as a decrease of at least about 50%, a decrease of at least about 70%, or a decrease of at least about 90, compared to the corresponding wild-type endostatin or a variant thereof. %.
- the ATPase activity of the mutant is retained only up to about 60-70%, such as up to about 50-60%, and up to about 40-50%, compared to the corresponding wild-type endostatin or a variant thereof. , retain up to approximately 30-40%, retain up to approximately 20-30%, retain up to approximately 10-20%, or retain less than 10% or less.
- the mutant does not have ATPase activity.
- the mutant comprises a mutation in its ATP binding motif as compared to the corresponding wild type endostatin or a variant thereof.
- the mutant comprises a mutation in a sequence corresponding to a Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues 89-95 of SEQ ID NO. 1, wherein The mutation is selected from the group consisting of a substitution, deletion or addition of one or several amino acid residues or a combination thereof, wherein the mutation results in a decrease or elimination of the ATPase activity of the mutant.
- the sequence of the mutant corresponding to the Gly-Ser-Glu-Gly-Pro-Leu-Lys motif consisting of amino acid residues 89-95 of SEQ ID NO. 1 is partially or
- the endostatin mutant of the invention comprises the following mutations: (a) the Gly amino acid residue corresponding to position 89 of SEQ ID NO. 1 is substituted with an amino acid selected from the group consisting of an uncharged amino acid or an aromatic Or deleted; or (b) the Gly amino acid residue corresponding to position 92 of SEQ ID NO. 1 is substituted or deleted from an uncharged amino acid; or (c) corresponds to the first of SEQ ID NO.
- the Lys amino acid residue at position 95 is substituted or deleted by an amino acid selected from a positively charged or uncharged amino acid; or (d) any combination of (a) to (c).
- the endostatin mutant of the present invention comprises the following mutations: (a) the Gly amino acid residue corresponding to position 89 of SEQ ID NO. 1 is substituted or deleted by an amino acid selected from Ala and Pro; (b) a Gly amino acid residue corresponding to position 92 of SEQ ID NO. 1 is substituted or deleted by Ala; or (c) a Lys amino acid residue corresponding to position 95 of SEQ ID NO. 1 is selected from Arg And amino acid substitutions or deletions of Gin; or (d) any combination of (a)-(c).
- the endostatin mutant of the invention comprises a sequence selected from the group consisting of SEQ ID NO. 6 - IK 13, 14, 15-27 and 30-31.
- the endostatin mutant of the invention comprises a sequence selected from the group consisting of: SEQ ID N0.6, SEQ ID ⁇ 10, SEQ ID N0.27 and SEQ ID NO.
- the above-described endostatin mutant of the present invention is a mutant of human endostatin.
- the present invention also provides a pharmaceutical composition comprising the endostatin mutant of the present invention as described above.
- the endostatin may be covalently linked to a PEG molecule.
- the molecular weight of the PEG molecule is, for example, 5-40 kD, such as 5-20 kD, or 20-40 kD, preferably the molecular weight of the PEG molecule is 20 kD, for example 20 kD monomethoxy polyethylene glycol For example, monomethoxy polyethylene glycol propionaldehyde (mPEG-ALD).
- the PEG molecule is covalently linked to the N-terminal alpha amino group of the endostatin.
- the present invention also provides a method of treating a tumor comprising administering to a tumor patient an endostatin mutant of the present invention as described above or a pharmaceutical composition of the present invention as described above.
- the present invention also relates to the use of an endostatin mutant as described above for the preparation of a medicament for treating a neovascular related disease.
- the neovascular related disease is a tumor.
- Endostatin was cloned from the cDNA of human hepatoma cell line A549 and ligated into the pET30a plasmid.
- the 5'-end primer used for gene amplification is GGAATTCCATATGCACAGCCACCGCGACTTC, and the end-end bow is CCGCTCGAGT TACTTGGAGGCAGTCATGAAGCTG.
- the endonucleases are Ndel and XhoI, respectively.
- Example 2 Construction of an ES or Endu mutant strain with ATP binding site mutation
- the ATP binding site of wild-type human ES was mutated, and the specific method and the upstream and downstream primers and transformation methods were the same as those in Example 1.
- the mutant numbers are as follows:
- ES003 is taken as an example to describe the expression and preparation method of ES and its mutant and Endu mutant as follows: ES and its mutant strains were incubated in LB medium for overnight incubation and then inoculated into 5L fermentor. Fermentation was carried out (Sartorius), and IPTG induction was added as appropriate, and the cells were collected after about 4 hours of culture (Fig. 2A). The cells were resuspended in buffer and thoroughly crushed by a high-pressure homogenizer, and repeatedly crushed three times, each time being centrifuged to leave a precipitate.
- the prepared sample or control sample was added to a final concentration of 500 ⁇ M, and placed in a 37 ° C water bath for 30 min, and then quenched in an ice bath for 5 min.
- the sample processing of the ES and its variants was performed in the same manner as the first group and in parallel with the first group.
- the two groups of samples are respectively diluted to appropriate multiples, and sequentially added to a 96-well microtiter plate, using a Malachite Green Phosphate Assay Kits (BioAssay Systems), and passed through a microplate reader (Multiskan mk3).
- ES, Endu and their mPEG modified products can significantly reduce ATP content in human vascular endothelial cell whole cell homogenate, thereby exerting ATPase activity.
- human vascular endothelial cells are first collected, and the cells are lysed into a whole cell lysis component in the form of a solution using a cell lysate, and the precipitate, impurities, and fragments of the cell homogenate are removed by centrifugation at a low temperature (the above operation is performed on ice).
- the cells were lysed into four groups and treated differently.
- the method of grouping was as follows. The first group: the negative control group, adding an equal volume of protein-free buffer; the second group, adding ES (50 g / mL) treatment; the third group, adding ES (100 g / mL) treatment; the fourth group, adding ES (200 g/mL) treatment.
- polyethylene glycol modified ES can also significantly decompose and reduce ATP levels in human vascular endothelial cell lysing fraction, only at the same dose of ES and mPEG-ES (respectively When 50, 100, 200 g/mL was added and the treatment time was the same, the activity of mPEG-ES to degrade ATP was slightly lower than that of ES (Fig. 4A).
- the ES may also be replaced with a protein having the same mechanism of action as ES or a variant thereof, Endu. Similar results were observed in a parallel comparison of Endu and its mPEG-modified product (mPEG-Endu) (i.e., mPEG-ALD, 20 kDa modified on the N-terminal with MGGSHHHHH additional amino acids).
- mPEG-Endu mPEG-modified product
- the whole cell lysate fraction of human vascular endothelial cells was obtained by the same experimental method as described in the present example, and divided into seven groups and treated differently.
- the treatment grouping method was as follows.
- the first group negative control group, no treatment; the second group, negative control group, treated with bovine serum albumin BSA (100 g/mL), BSA is a known protein without ATPase activity, often used as Negative control protein in this type of experiment; the third group, the positive control group, was treated with porcine myosin (100 g/mL), a known protein with high ATPase activity.
- the fourth group added ES (100 g / mL) treatment; the fifth group, added mPEG-ES (100 g / mL) treatment; the sixth group, added Endu (100 g / mL) treatment; Seven groups were treated with mPEG-Endu (100 g/mL).
- mPEG-ES the native sequence ES has the highest ATPase activity, close to Myosin; mPEG-ES has the second highest ATPase activity, slightly lower than ES; Endu and mPEG-Endu ATPase activity was lower (Fig. 4B).
- Example 6 Evaluation of ATPase activity is a convenient, accurate, and reproducible method for measuring the activity of ES.
- ES, Endu, mPEG-ES and mPEG-Endu were diluted with sample dilution in a bath condition to form a series of concentration gradient samples to be tested (specific concentrations are shown in Figure 5).
- the diluted sample was added to a 96-well microtiter plate, and each sample was examined for OD 63 using a Malachite Green Phosphate Assay Kits (BioAssay Systems). Absorbance value. Calculate the dilution based on the dilution factor of the sample After the sample concentration, and calculate the corresponding A OD 63 . .
- a OD 630 S1 (OD 630 )- S2 (OD 630 )
- Example 5 Human vascular endothelial cells were collected, and the cells were lysed into a whole cell lysis component in the form of a solution using a cell lysate, and the precipitate, impurities and fragments of the cell homogenate were removed by centrifugation at a low temperature; The lysis components are divided into arrays and processed differently.
- the processing grouping method is as follows.
- Group 1 Negative control group, no ES (addition of equal buffer solution); Group 2, ES (100 g/mL) treatment; Group 3, add mouse-derived endostatin MM (100 g /mL) treatment; the fourth group, added ES mutant ES003 (100 g / mL) treatment; the fifth group, added ES mutant ES006 (100 g / mL) treatment; the sixth group, added ES mutant ES007 (100 g/mL) treatment; Group 7, was treated with ES mutant ES008 (100 g/mL).
- the ATP content in the homogenate of each group was detected using an ATP bioluminescence assay kit Sigma-Aldrich.
- HMEC Human microvascular endothelial cells
- the same concentration of ES (20 g/mL) was added to the upper and lower layers of the basket.
- the cells were allowed to migrate by incubating for 6 hours at 37 ° C and 5% CO 2 .
- glutaraldehyde fixation and crystal violet staining 5 magnified fields of view were randomly selected for each well, and the number of cells that completely migrated through the membrane to the underlying layer was calculated and averaged, and cell migration was calculated compared with the control group.
- the number of cases decreased (ie, the inhibition rate of each histone).
- Each set was paralleled with three wells and the experiment was repeated at least twice independently.
- endothelial cell HMEC was divided into the following groups to be treated differently.
- Group 1 Negative control group, no ES (addition of equal buffer solution);
- Group 3, add mouse-derived endostatin MM (20 g /mL) treatment;
- the fourth group added ES mutant ES003 (20 g / mL) treatment;
- the fifth group added ES mutant ES006 (20 g / mL) treatment;
- the sixth group added ES mutant ES007 (20 g/mL) treatment;
- Group 7 was treated with ES mutant ES008 (20 g/mL).
- the results showed that the activity of MM, mutants ES003, ES006, ES007, and ES008 to inhibit endothelial cell migration was significantly increased compared with ES (Fig. 8A).
- Example 1 Mutating the ATP-binding motif of wild-type ES and its surrounding sequences, To mutants with reduced ATP activity
- Example 12 Effect of ES mutants on migration of HMEC cells
- the cell migration assay was evaluated using the Transwell Assay method described in Example 9. Since many mutant proteins inhibit the activity of endothelial cell migration significantly, in order to more clearly reflect the difference in activity between each mutant protein, this example can still see significant inhibition by treating cells with a reduced dose of 5 g/mL. effect.
- the experimental results are shown in Figures 43-47. In addition to the lowering of ATPase activity of Z103, Z104, ZN3 and ZN4, the activity of inhibiting endothelial cell migration was also decreased. All other mutants showed comparable or significantly increased activity of inhibiting endothelial cell migration with ES, in line with ATPase. The activity is inversely related to the activity of inhibiting endothelial cell migration.
- Example 13 Inhibitory effect of Endostatin mutant on tumor growth of non-small cell lung cancer A549 cells at the animal level
- this experiment used a reduced dose of 12 mg / kg to treat tumor-bearing mice (usually 24 mg / kg) o
- Group 1 Negative control group, no drug treatment, Only the same amount of normal saline was injected; the second group, the mPEG-ES administration group, was treated with mPEG-ES; the third group, the M003 administration group, was treated with M003; the fourth group, the M007 administration group, The M007 administration treatment was carried out; the fifth group, the MZ101 administration group, was subjected to MZ101 administration treatment.
- the results of the tumor volume growth assay showed (as shown in Figure 48A) that compared with the tumor volume of the first group of controls without drug treatment: the tumor volume inhibition rate of the second group of mPEG-ES administration was 45%; The tumor volume inhibition rate of the three groups of M003 and the fourth group of M007 was similar to that of mPEG-ES; the tumor volume inhibition rate of the fifth group of MZ101 administration was 71.2%, and the tumor volume of this group was the smallest. The drug has the highest tumor inhibition rate.
- the tumors of the tumor-bearing nude mice were taken out for weighing (as shown in Fig. 48B), and the inhibitory effect of each group of drug treatment on tumor weight was consistent with the results of the tumor volume determination experiment.
- the tumor weight inhibition rate of the second group of MS03 administration was 42%
- the tumor weight inhibition rate of the third group of M003 and the fourth group of M007 administration and mPEG-ES was 64%, and the tumor weight of this group was the smallest and the drug inhibition rate was the highest.
- the results of this example demonstrate that Endostatin mutants at a dose of 12 mg/kg/week have a good inhibitory effect on tumor growth in tumor-bearing animal experiments.
- the inhibition rate of mPEG-ES is about 40%; the inhibition rate of M003 and M007 is close to and slightly lower than that of mPEG-ES; the anti-tumor effect of MZ101 is better than that of mPEG-ES, the best effect and the highest tumor inhibition rate (about 60-70%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014113924/10A RU2014113924A (ru) | 2011-09-09 | 2012-09-10 | Мутанты эндостатина с мутациями в сайтах связывания атф |
CN201280078261.4A CN108291248B (zh) | 2011-09-09 | 2012-09-10 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
CN202410186085.0A CN117987505A (zh) | 2011-09-09 | 2012-09-10 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
US14/343,694 US10647968B2 (en) | 2011-09-09 | 2012-09-10 | Endostatin mutants with mutations at ATP binding sites |
CA2848118A CA2848118C (en) | 2011-09-09 | 2012-09-10 | Endostatin mutants with mutations at atp binding sites |
EP12830317.9A EP2754718B1 (en) | 2011-09-09 | 2012-09-10 | Vascular endothelial myostatin mutant that mutates at atp binding sites |
AU2012306826A AU2012306826B2 (en) | 2011-09-09 | 2012-09-10 | Endostatin mutants with mutations at ATP binding sites |
JP2014528847A JP6336389B2 (ja) | 2011-09-09 | 2012-09-10 | Atp結合部位に変異を有するエンドスタチン変異体 |
IL231419A IL231419A0 (en) | 2011-09-09 | 2014-03-09 | Mutations of endo-statin with mutations in atp binding sites |
HK18110856.2A HK1251864A1 (zh) | 2011-09-09 | 2018-08-23 | 對atp結合位點進行突變的血管內皮抑制素突變體 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110280441.8 | 2011-09-09 | ||
CN201110280441 | 2011-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013034116A1 true WO2013034116A1 (zh) | 2013-03-14 |
Family
ID=47831548
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2012/081210 WO2013034116A1 (zh) | 2011-09-09 | 2012-09-10 | 对atp结合位点进行突变的血管内皮抑制素突变体 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10647968B2 (zh) |
EP (1) | EP2754718B1 (zh) |
JP (1) | JP6336389B2 (zh) |
CN (2) | CN117987505A (zh) |
AU (1) | AU2012306826B2 (zh) |
CA (1) | CA2848118C (zh) |
HK (1) | HK1251864A1 (zh) |
IL (1) | IL231419A0 (zh) |
RU (1) | RU2014113924A (zh) |
WO (1) | WO2013034116A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015139511A1 (zh) * | 2014-03-19 | 2015-09-24 | 北京仁和天通生物科技有限公司 | Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用 |
WO2016127948A1 (zh) * | 2015-02-13 | 2016-08-18 | 清华大学 | 一种重组蛋白质药物的分子设计 |
CN107148277A (zh) * | 2014-11-03 | 2017-09-08 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110452295B (zh) * | 2015-11-10 | 2022-10-11 | 孙嘉琳 | 抗肿瘤蛋白内皮抑素的衍生物 |
JP7140454B2 (ja) * | 2016-11-10 | 2022-09-21 | ベイジン プロトゲン リミテッド | ペグ化エンドスタチン類似体およびその適用 |
WO2019024814A1 (zh) * | 2017-07-30 | 2019-02-07 | 清华大学 | 抑制dna依赖蛋白激酶催化亚基的药物 |
CN114645025B (zh) * | 2022-04-13 | 2023-12-22 | 南开大学 | 一种人源atp合成酶的纯化方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324818A (zh) * | 2000-05-22 | 2001-12-05 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
CN101002946A (zh) * | 2006-01-20 | 2007-07-25 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
US7339027B2 (en) * | 2002-05-31 | 2008-03-04 | Ghc Research Development Corporation | Human prolactin antagonist-angiogenesis inhibitor fusion proteins |
CN101256139A (zh) * | 2008-04-18 | 2008-09-03 | 山东先声麦得津生物制药有限公司 | 一种血管内皮抑制素生物活性的检测方法 |
US20110092441A1 (en) * | 2008-04-04 | 2011-04-21 | Procell Therapeutics Inc | Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010015867A (ko) * | 1997-12-08 | 2001-02-26 | 베쓰 이스라엘 디코니스 메디칼 센터 | 항-혈관형성 활성을 지니고 있는, 엔도스타틴의 변이체인"em 1" 및 이것을 사용하는 방법 |
AU4982200A (en) * | 1999-05-06 | 2000-11-21 | Burnham Institute, The | Antiangiogenic endostatin peptides, endostatin variants and methods of use |
CN101143894A (zh) * | 2007-06-22 | 2008-03-19 | 中国药科大学 | 高效抑制血管生成多肽及其物理化学修饰方法和应用 |
CN101890155B (zh) * | 2010-05-25 | 2012-07-25 | 江苏先声药物研究有限公司 | 一种药物组合物及其应用 |
-
2012
- 2012-09-10 AU AU2012306826A patent/AU2012306826B2/en active Active
- 2012-09-10 CA CA2848118A patent/CA2848118C/en active Active
- 2012-09-10 CN CN202410186085.0A patent/CN117987505A/zh active Pending
- 2012-09-10 WO PCT/CN2012/081210 patent/WO2013034116A1/zh active Application Filing
- 2012-09-10 EP EP12830317.9A patent/EP2754718B1/en active Active
- 2012-09-10 RU RU2014113924/10A patent/RU2014113924A/ru not_active Application Discontinuation
- 2012-09-10 US US14/343,694 patent/US10647968B2/en active Active
- 2012-09-10 CN CN201280078261.4A patent/CN108291248B/zh active Active
- 2012-09-10 JP JP2014528847A patent/JP6336389B2/ja active Active
-
2014
- 2014-03-09 IL IL231419A patent/IL231419A0/en active IP Right Grant
-
2018
- 2018-08-23 HK HK18110856.2A patent/HK1251864A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324818A (zh) * | 2000-05-22 | 2001-12-05 | 烟台荣昌生物工程有限公司 | 生产内皮抑制素的方法 |
US7339027B2 (en) * | 2002-05-31 | 2008-03-04 | Ghc Research Development Corporation | Human prolactin antagonist-angiogenesis inhibitor fusion proteins |
CN101002946A (zh) * | 2006-01-20 | 2007-07-25 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
CN100475270C (zh) | 2006-01-20 | 2009-04-08 | 清华大学 | 一种治疗肿瘤的药物及其应用 |
US20110092441A1 (en) * | 2008-04-04 | 2011-04-21 | Procell Therapeutics Inc | Cell-permeable endostatin recombinant protein, a polynucleotide encoding the same, and an anti-cancer preparation containing the same as an active component |
CN101256139A (zh) * | 2008-04-18 | 2008-09-03 | 山东先声麦得津生物制药有限公司 | 一种血管内皮抑制素生物活性的检测方法 |
Non-Patent Citations (28)
Title |
---|
ANDREA T. DEYRUP ET AL., JBC, vol. 273, no. 16, 1998, pages 9450 - 9456 |
AUSUBEL ET AL.: "Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology", 2002, WILEY, JOHN& SONS, INC. |
CHEN Y ET AL., BLOOD, vol. 117, 2011, pages 6392 - 6403 |
COLIGAN ET AL.: "Short Protocols in Protein Science", 2003, WILEY, JOHN& SONS, INC. |
DRISCOLL, W. J. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 92, 1995, pages 12328 - 12332 |
FOLKMAN J. ET AL., CELL, vol. 88, 1997, pages 277 - 285 |
FOLKMAN J. ET AL., NATURE, vol. 390, 1997, pages 404 - 407 |
FU Y. ET AL., BIOCHEMISTRY, vol. 49, 2010, pages 6420 - 6429 |
GUOYING MOU, DISSERTATION OF SHANDONG UNIVERSITY, 2005 |
HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY PRESS |
JAVAHERIAN, K. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 45211 - 45218 |
KARUMANCHI, S. ET AL., MOL. CELL, vol. 7, 2001, pages 811 - 822 |
KIM, Y. M. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 27872 - 27879 |
LEE, S. J. ET AL., FEBS LETT., vol. 519, 2002, pages 147 - 152 |
LI YH ET AL., CHIN J BIOLOGICAL, vol. 24, no. 3, March 2011 (2011-03-01), pages 320 - 323 |
MACDONALD, N. J. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 25190 - 25196 |
MATTHEW G. ET AL., SCIENCE, vol. 324, 2009, pages 1029 - 1033 |
ROBERT TJINTHAMSJIN ET AL., CANCER RES., vol. 65, no. 9, 2005, pages 3656 - 63 |
SAMBOOK J.; RUSSELL D.: "Molecular Cloning: A Laboratory Manual", 2000, COLD SPRING HARBOR LABORATORY PRESS |
SATISHCHANDRAN, C. ET AL., BIOCHEMISTRY, vol. 31, 1992, pages 11684 - 11688 |
SCIENCE, vol. 295, 2002, pages 2198 - 2199 |
SHI HB ET AL., BLOOD, vol. 110, 2007, pages 2899 - 2906 |
SUDHAKAR, A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 4766 - 4771 |
SVEN CHRIDTIAN ET AL., JBC, vol. 163, no. 4, 2003, pages 871 - 878 |
THOMAS, P.M. ET AL., AM. J. HUM. GENET., vol. 59, 1995, pages 510 - 518 |
TONG-YOUNG LEE ET AL., CLIN CANCER RES, vol. 14, no. 5, 2008, pages 1487 - 1493 |
WALKER, J. ET AL., EMBO J., vol. 1, 1982, pages 945 - 951 |
YUAN, SHAOPENG: "Studies on the Mechanism of Human Endostatin-induced Endothelial Cell Apoptosis", CHINA DOCTORAL DISSERTATIONS FULL-TEXT DATABASE (E-JOURNAL), MEDICINE & HYGIENE 2009, no. 8, 15 August 2009 (2009-08-15), pages 35, XP008173764 * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015139511A1 (zh) * | 2014-03-19 | 2015-09-24 | 北京仁和天通生物科技有限公司 | Endostatin突变体、Endostatin突变体与聚乙二醇的交联物以及它们的应用 |
CN107148277B (zh) * | 2014-11-03 | 2022-03-22 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
CN107148277A (zh) * | 2014-11-03 | 2017-09-08 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
JP2018501195A (ja) * | 2014-11-03 | 2018-01-18 | 清華大学Tsinghua University | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
JP2020172546A (ja) * | 2014-11-03 | 2020-10-22 | 清華大学Tsinghua University | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
CN114558111A (zh) * | 2014-11-03 | 2022-05-31 | 清华大学 | 一种抑制脂肪细胞分化和胰岛素耐受的药物 |
US20220409703A1 (en) * | 2014-11-03 | 2022-12-29 | Tsinghua University | Drug for inhibiting adipose cell differentiation and insulin resistance |
JP7227197B2 (ja) | 2014-11-03 | 2023-02-21 | 清華大学 | 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 |
CN107428809A (zh) * | 2015-02-13 | 2017-12-01 | 清华大学 | 一种重组蛋白质药物的分子设计 |
US20180200337A1 (en) * | 2015-02-13 | 2018-07-19 | Tsinghua University | Molecular design of recombinant protein drug |
US10869910B2 (en) | 2015-02-13 | 2020-12-22 | Tsinghua University | Molecular design of recombinant protein drug |
CN107428809B (zh) * | 2015-02-13 | 2021-10-01 | 清华大学 | 一种重组蛋白质药物的分子设计 |
WO2016127948A1 (zh) * | 2015-02-13 | 2016-08-18 | 清华大学 | 一种重组蛋白质药物的分子设计 |
CN114249816A (zh) * | 2015-02-13 | 2022-03-29 | 清华大学 | 一种重组蛋白质药物的分子设计 |
Also Published As
Publication number | Publication date |
---|---|
CA2848118C (en) | 2023-09-05 |
EP2754718B1 (en) | 2017-12-13 |
CN108291248A (zh) | 2018-07-17 |
CN117987505A (zh) | 2024-05-07 |
US10647968B2 (en) | 2020-05-12 |
AU2012306826A1 (en) | 2014-04-03 |
JP2014531897A (ja) | 2014-12-04 |
IL231419A0 (en) | 2014-04-30 |
HK1251864A1 (zh) | 2019-04-26 |
US20140308263A1 (en) | 2014-10-16 |
CA2848118A1 (en) | 2013-03-14 |
JP6336389B2 (ja) | 2018-06-06 |
EP2754718A4 (en) | 2015-04-22 |
AU2012306826B2 (en) | 2018-01-04 |
CN108291248B (zh) | 2024-03-08 |
RU2014113924A (ru) | 2015-10-20 |
US20150197733A9 (en) | 2015-07-16 |
EP2754718A1 (en) | 2014-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2013034116A1 (zh) | 对atp结合位点进行突变的血管内皮抑制素突变体 | |
US8334101B2 (en) | Intracellular DNA receptor | |
DK2406399T3 (en) | MIRAC PROTEINS | |
RU2756318C2 (ru) | Мутеины липокалина 2 человека с аффинностью в отношении глипикана-3 (gpc3) | |
Yadav et al. | Molecular insights on cytochrome c and nucleotide regulation of apoptosome function and its implication in cancer | |
JP2021534776A (ja) | リコンビナントタンパク質変異体 | |
KR20220058586A (ko) | 치료용 융합 단백질 | |
US20100285033A1 (en) | COMPOSITIONS AND METHODS FOR CaMKII INHIBITORS AND USES THEREOF | |
US20210309984A1 (en) | ChiA Enzyme | |
JPWO2010116899A1 (ja) | Ptenのリン酸化抑制剤又は脱リン酸化剤 | |
TW202142241A (zh) | 用於治療疾病或病症之方法及組合物 | |
WO2020165570A1 (en) | Methods relating to disrupting the binding of af9 partner proteins to af9 and/or enl | |
Ali et al. | Leishmania mexicana: expression, characterization and activity assessment of E. coli-expressed recombinant CRK3 | |
US7060456B2 (en) | Regulation of human protein phosphatase IIc-like enzyme | |
JP4232423B2 (ja) | 新規ユビキチン特異プロテアーゼ | |
JPWO2006070804A1 (ja) | テロメレース活性阻害方法および阻害剤 | |
WO2008029807A1 (fr) | Nouveau polypeptide ayant une cytotoxicité contre le cancer, procédé pour cribler le polypeptide et utilisation du polypeptide | |
JPWO2005110476A1 (ja) | テロメレース活性阻害方法および阻害剤 | |
Weng et al. | Both IRAK3 and IRAK1 Activate the MyD88–TRAF6 Pathway in Zebrafish | |
Kim et al. | Functional analysis of duplicated genes and N-terminal splice variant of phospholipase C-δ1 in Paralichthys olivaceus | |
Rolfes | Apoptosis and cell cycle regulation in a basal model system: insights from the placozoan Trichoplax adhaerens | |
WO2015174641A1 (ko) | Aimp2-dx2-34s 단백질 및 이의 제조방법 | |
CA2390371A1 (en) | Antibiotics based upon bacteriophage lysis proteins | |
JP2005192567A (ja) | チロシンキナーゼ遺伝子およびその遺伝子産物 | |
US20070020269A1 (en) | Phosphokinase and the usage thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12830317 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2014528847 Country of ref document: JP Kind code of ref document: A Ref document number: 2848118 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 231419 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012830317 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2012306826 Country of ref document: AU Date of ref document: 20120910 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014113924 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201280078261.4 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14343694 Country of ref document: US |